Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Outset Medical, Inc. filing an amendment to a Schedule 13G that updates beneficial ownership for BML Investment Partners, L.P. The filing reports 2,196,701 shares of Common Stock and a 11.8% ownership stake, with shared voting and dispositive power reported.
The filing states that BML Investment Partners, L.P. is a Delaware limited partnership; BML Capital Management, LLC is its sole general partner and Braden M. Leonard is the managing member, who is deemed an indirect owner of the reported shares. The signature is dated 05/12/2026.
Outset Medical, Inc. insider activity shows entities associated with Michael Leonard exercising in-the-money derivatives to acquire additional common stock. BML Investment Partners, L.P. acquired 197,600 and 96,900 shares of common stock at $5.00 per share, bringing its indirectly held position to 2,196,701 shares. These holdings are managed by BML Capital Management, LLC, where Leonard is the managing member with investment and voting control, while he disclaims beneficial ownership beyond his pecuniary interest. The filing also notes outstanding indirect positions in short put options over additional common shares.
Outset Medical, Inc. reported first-quarter 2026 revenue of $27.9 million, down 6% from $29.8 million a year earlier, as lower product revenue offset growth in services. Recurring Tablo consumables and service revenue was $22.5 million, roughly flat with the prior-year period.
Gross profit rose to $12.1 million and gross margin expanded to 43.4% from 37.2%, helped by record product gross margin of 52.4% and service and other gross margin of 25.5%. GAAP net loss narrowed to $19.0 million, or $1.03 per share, compared with a $25.8 million loss. On a non-GAAP basis, net loss was $15.4 million versus $22.8 million.
Operating expenses increased to $29.0 million from $27.5 million, reflecting higher general and administrative spending, including stock-based compensation and litigation charges. Total cash, including restricted cash, cash equivalents and investments, was about $160.5 million as of March 31, 2026. The company reiterated 2026 revenue guidance of $125–$130 million, a 5% to 9% increase over $119.5 million in 2025, and continues to target non-GAAP gross margin in the low to mid-40% range.
Outset Medical, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026 at 1:30 p.m. Pacific Time. Holders of 18,529,233 common shares as of April 9, 2026 may vote on electing two Class III directors, an advisory say‑on‑pay resolution, and ratifying KPMG LLP as independent auditor for 2026.
The company highlights 2025 net revenue of $119.5 million, 6% growth in recurring revenue to $88.7 million, and gross margin of 39.1% (39.6% non‑GAAP). It also describes board structure, governance practices, stock ownership and recoupment policies, and an executive pay program that mixes salary, annual bonuses and performance‑based equity.
Elliott Derick A. reported acquisition or exercise transactions in this Form 4 filing.
Outset Medical, Inc. executive Elliott Derick A., EVP, Commercial, received a grant of 96,000 shares of common stock in the form of restricted stock units at $0.00 per share as equity compensation. The RSUs vest 33.33% on April 6, 2027, with the remaining 66.66% vesting in equal quarterly installments over the next two years, subject to continuous service. Following this award, he holds 96,000 shares directly.
Outset Medical, Inc. executive Elliott Derick A., listed as EVP, Commercial, filed an initial Form 3 insider ownership report. This filing identifies him as a reporting officer of the company and, in the data shown, does not include any buy, sell, or derivative transactions.
Outset Medical Inc reports a Schedule 13G/A filing from The Vanguard Group disclosing zero shares beneficially owned.
The filing states Amount beneficially owned: 0 and Percent of class: 0%. It explains that on January 12, 2026 Vanguard completed an internal realignment and certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.
Outset Medical, Inc. insider ownership has been updated in an amended Form 3. The amendment reflects indirect holdings by BML Investment Partners, L.P., including short put options tied to 617,500 and 110,000 shares of Outset Medical and 1,902,201 shares of common stock. The filing states these derivative securities were previously omitted due to a clerical error.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 2,842 shares of Common Stock at $3.35 per share in an open-market transaction. According to the footnote, this was a required “sell to cover” sale to satisfy tax withholding on 5,032 vesting RSU shares and was not a discretionary trade. Following the transaction, he directly owned 32,935 shares of Common Stock.